Diffuse large B-cell lymphoma trials in China

In China 133 Also abroad 346

133 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
Where
Xiamen
Age
18 years to 70 years
People
38
Run by
The First Affiliated Hospital of Xiamen University
See details and how to joinNCT06151080
Phase 2Taking people
AZA Combined With RCHOP in P53-mutated DLBCL.
Where
Xiamen
Age
18 years to 70 years
People
52
Run by
The First Affiliated Hospital of Xiamen University
See details and how to joinNCT06158399
No phaseTaking people
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL
Where
Shanghai
Age
18 years and over
People
400
Run by
Ruijin Hospital
See details and how to joinNCT06779435
No phaseTaking people
Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
Where
Hangzhou
Age
18 years to 75 years
People
44
Run by
Zhejiang Cancer Hospital
See details and how to joinNCT06832267
Phase 1Taking people
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
Where
Hangzhou
Age
18 years to 75 years
People
52
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06464861
Phase 2Not yet taking people in China
AZA Combined with R-GemOx for Elderly DLBCL Patients
Where
Chongqing
Age
60 years to 90 years
People
80
Run by
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
See details and how to joinNCT06778902
No phaseTaking people
PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
Where
Shanghai
Age
18 years and over
People
150
Run by
Ruijin Hospital
See details and how to joinNCT06755775
Phase 2Taking people
CR-CHOP+X in Previously Untreated DEL
Where
Shanghai
Age
18 years to 75 years
People
49
Run by
Ruijin Hospital
See details and how to joinNCT06701357
Phase 2Not yet taking people in China
CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p)
Where
Shanghai
Age
18 years to 75 years
People
34
Run by
Ruijin Hospital
See details and how to joinNCT06750991
No phaseTaking people
Real-World Study of DLBCL With Different Genetic Subtypes
Where
Shanghai
Age
18 years and over
People
10,000
Run by
Ruijin Hospital
See details and how to joinNCT06026488
Phase 1/2Taking people
A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma
Where
Zhengzhou
Age
65 years and over
People
80
Run by
Mingzhi Zhang
See details and how to joinNCT06683885
No phaseNot yet taking people in China
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
Where
Shanghai
Age
18 years and over
People
200
Run by
Ruijin Hospital
See details and how to joinNCT06656234
Phase 2Taking people
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
Where
Dongguan, Guangzhou, Lanzhou, Shantou, Shenzhen, Zhaoqing, Zhuhai
Age
18 years and over
People
39
Run by
Sun Yat-sen University
See details and how to joinNCT06647940
Phase 2Not yet taking people in China
High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)
Where
Guangzhou
Age
18 years to 70 years
People
30
Run by
Sun Yat-sen University
See details and how to joinNCT06646211
Phase 2Taking people
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
Where
Beijing
Age
14 years and over
People
240
Run by
Navy General Hospital, Beijing
See details and how to joinNCT06503263
Phase 2Not yet taking people in China
Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement
Where
Nanjing
Age
18 years to 80 years
People
40
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT06594432
Phase 1Taking people
Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
Where
Tianjin
Age
18 years and over
People
25
Run by
Beijing Yongtai Ruike Biotechnology Company Ltd
See details and how to joinNCT06047197
Phase 2Taking people
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients
Where
Guangzhou
Age
18 years and over
People
38
Run by
Sun Yat-sen University
See details and how to joinNCT06569485
Phase 2Taking people
A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
Where
Hanzhou
Age
18 years to 75 years
People
36
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06554600
Phase 3Taking people
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
Where
Shanghai
Age
70 years and over
People
100
Run by
Ruijin Hospital
See details and how to joinNCT06522555
Phase 2Taking people
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
Where
Hangzhou
Age
18 years to 65 years
People
260
Run by
Zhejiang Provincial People's Hospital
See details and how to joinNCT06534762
Phase 3Taking people
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Where
Beijing, Changchun, Changsha, Chaozhou, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shanghai, Suzhou, Tianjin, Ürümqi, Wenzhou, Wuhan, Zhengzhou
Age
18 years and over
People
244
Run by
Beijing InnoCare Pharma Tech Co., Ltd.
See details and how to joinNCT06521255
Phase 1Taking people
An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Where
Shanghai
Age
18 years and over
People
9
Run by
Fudan University
See details and how to joinNCT06517004
No phaseNot yet taking people in China
Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL
Where
Suzhou
Age
18 years and over
People
30
Run by
Second Affiliated Hospital of Soochow University
See details and how to joinNCT06289959
Phase 2Taking people
Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
Where
Beijing
Age
70 years and over
People
30
Run by
Yan Zhang, MD
See details and how to joinNCT06176729